Isoproterenol produced an increase in pulmonary blood volume and pulmonary blood flow without a significant change in pulmonary vascular pressures in 14 patients with obstructive lung disease, six of whom had cor pulmonale. These findings are consistent with a vasodilating effect on the pulmonary vasculature. Evidence is presented that muscular pulmonary arteries constricted by hypoxia were affected by the drug. There is little to suggest that the compliance of the elastic arteries was altered by isoproterenol.
I SOPROTERENOL, a powerful inotropic and chronotropic agent, is also reported to be a dilator of the pulmonary vasculature.1-7 Studies in patients with valvular heart disease and primary myocardial disease have shown that this drug will produce a slight fall in pulmonary arterial and pulmonary wedge pressures and an increase in pulmonary blood volume, findings compatible with vasodilatation. 3 6 Similar definitive studies have not been made in patients with chronic obstructive lung disease or cor pulmonale, although there is evidence that the drug may produce a fall in pulmonary arterial blood pressures.4 5 The present study was undertaken to define more completely the effect of this drug on patients with chronic obstructive lung disease and, in particular, to assess its effects on pulmonary blood volume, the abnormal pulmonary diastolic pressure gradient across the lungs which these patients display,8 and the compliance characteristics of the elastic pulmonary arteries.
Methods
Fourteen patients with chronic obstructive pulmonary disease and normal sinus rhythm were examined (tables 1 and 2). Six of the 14 patients had evidence of cor pulmonale. Only one (1644a) was in right ventricular failure at the time of study; he was studied again after right ventricular failure had subsided (1644b). The remaining five patients with cor pulmonale were studied after recovery from right ventricular failure. Six patients had no heart disease. Two patients had left ventricular disease as well as chronic obstructive lung disease: one had right and left ventricular enlargement and failure at the time of study. The origin of his left ventricular disease was not identified. The To define the types of chronic obstructive lung disease, we utilized the classification of Nash, Briscoe, and Cournand. 9 They have described two major categories: type A-patients who display cough, occasional scanty sputum, fixed dyspnea, thin habitus, large translucent lungs with low diaphragms and small cardiothoracic ratio, absence of cor pulmonale, and a normal hematocrit; type B-patients who manifest much cough and sputum, fluctuating dyspnea, normal or stout habitus, normal appearing lung fields and normal position of the diaphragm on X-ray, normal or increased cardiothoracic ratio, congestive failure due to cor pulmonale, and a high hematocrit Each patient had the protocol explained to him in detail, and his written permission was secured for all procedures. The day before the study, the patients were familiarized with the respiratory equipment. They were studied in the nonsedated, postabsorptive basal state.
Two double-lumen catheters were placed: one in the pulmonary artery for measurement of the pulmonary wedge and pulmonary arterial blood pressures and blood gases; the other in the right atrium with the tip adjacent to the tricuspid valve. The distal lumen of this second catheter was used to inject radioiodinated 1311 human serum albumin (Risa-131) for the measurement of cardiac output and pulmonary blood volume by the radiocardiographic technique. The proximal lumen was utilized for the infusion of the drug and measurement of right atrial mean pressure. A brachial artery was cannulated for measurement of systemic blood pressure, blood gases, and blood pH.
A control period, during which only isotonic saline was infused, lasted 20 to 30 min. Isoproterenol, as a solution of 0.8 mg in 500 ml of 5% dextrose in water, was then infused for 10 to 26 min at a rate of 3.3 to 5.0 gg/min. Systemic and pulmonary arterial blood pressures, the pulmonary wedge and right atrial pressures, and heart rate were recorded every 5 to 10 min during the control period and every 3 to 5 min during the infusion of the drug. The electrocardiogram was constantly monitored. Total blood volume was measured at the end of the control period and, in four instances, at the end of The response to isoproterenol was fairly uniform despite the heterogeneity of the patients ( fig. 1) .
The onset of the drug effect was always signalled by a rise in sinus rate and change in the contour of the brachial arterial pressure curve,16 and was usually noted 5 to 7 min after the beginning of the drug infusion.
The cardiac output (table 1) during the control period varied from low to slightly elevated, and rose strikingly during the administration of the drug in all subjects. There was a significant relationship between the initial level of blood flow and the percentage increase in cardiac output (r= -0.581, P < 0.025); thus, those with the lowest levels sustained the greatest increase. Although the initial level of cardiac output bore no relationship to the initial level of right atrial mean pressure (P < 0.20), the change in cardiac output was found to be closely related to the initial level of right atrial mean pressure (r = 0.834, P < 0.001). Thus, the higher the initial level of right atrial mean pressure, the greater the increase in cardiac output ( fig. 2) wedge pressure and either the initial level of blood flow (P < 0.10) or its change (P < 0.20). The change in cardiac output showed no relationship to change in heart rate (P <0.50).
Heart rate and stroke volume increased significantly. However, in five subjects the Initial level of right atrial mean pressure (mm Hg) Figure 2 Graphic representation of the relationship between the change in cardiac output induced by isoproterenol and the initial level of right atrial mean pressure.
latter did not change, and in the one patient (1612, table 1) whose heart rate rose the most, stroke volume actually declined 12 ml (-20%).
After isoproterenol infusion, pulmonary blood volume and the ratio of pulmonary blood volume to total blood volume rose in all but three patients. The pulmonary mean transit time did not change (P < 0.20). Although there was no significant relationship between the control level of systemic arterial oxyhemoglobin saturation and pulmonary blood volume (P < 0.10), those with the lowest initial oxygen saturations sustained the greatest percentage increase in pulmonary blood volume after the drug (r = -0.677, P <0.02), as shown in figure 3 . The relationship between the change in oxygen saturation and the change in pulmonary blood volume was of borderline significance (P < 0.05). The initial level of pulmonary blood volume bore no relationship to the initial level of blood hydrogen ion concentration (P < 0.60) or to ventilation (P < 0.20); nor did change in hydrogen ion concentration or ventilation bear any relationship to the change in pulmonary blood volume (P <0.30 and P < 0.25, respectively).
Brachial arterial diastolic and mean presCirculation, Volume XLIII, April 1971 sures fell slightly after infusion of the drug, while the systolic pressure did not change significantly. During the control period, the level of pulmonary arterial pressures ranged from normal to markedly elevated in these 14 patients. The diastolic pressure gradient across the lung (pulmonary arterial diastolic pressure minus mean pulmonary wedge pressure) ranged from slight to marked. The pulmonary wedge pressure in all but two patients was within normal limits.
Viewing the patients as a group, there was no difference in the levels of pulmonary arterial systolic or mean pressure before and after drug administration. There were, however, variations noted in both these pressures in individuals within the group, which could be related significantly to changes in diastolic pressure and stroke volume.
The pulmonary arterial systolic and mean pressures prior to and after drug infusion were predicted from equations 1 and 2. The relationship between observed and calculated systolic pressures was highly significant both prior to drug administration (r = 0.971, P < 0.001) and after isoproterenol infusion ( r = 0.948, P < 0.001). Further, the two relationships did not differ significantly from each other (P>0.40). Figure 4 (Top framne) graphic representation of the relationsA between pulmonary arterial systolic pressure, c culated accordinig to the equation given at the t of the figure, and systolic pressure during the two study periods ( fig. 4) is indicated by the fact that neither their slopes nor their intercepts differed significantly (P > 0.2 and P > 0.4, respectively). Further, neither intercept differed significantly from zero (P> 0.5). The relationship between observed and calculated mean pressures was highly significant both during the +0.5 +1.0 +1.5 +2.0 +2.5 +3.0 +3.5
Change in blood flow (L/minim2) Figure 5 Graphic representation of the relationship between the change in the pulmonary diastolic pressure gradient (pulmonary arterial diastolic pressure minus the mean pulmonary arterial wedge pressure) and the increase in blood flow induced by the administration of isoproterenol. after the infusion of the drug could be related to changes in the level of blood flow (r = 0.533, P <0.025). Thus, the gradient rose in those patients who sustained a large increase in flow, while it remained unchanged or fell in those with a lesser rise ( fig. 5) . Changes in the pressure gradient could not be related to changes in heart rate (P > 0.90) or to changes in ventilation (P > 0.90). The right atrial mean pressure was within normal limits in 12 of the 14 patients and, if the group is considered as a whole, there was no significant difference following administration of the drug. However, the two patients in whom this pressure was elevated in the control period did sustain a fall of 3 mm Hg at 11 and 15 min after the drug was started.
During the administration of the drug, minute ventilation increased and was accompanied by a slight rise in blood pH. In the control period, systemic arterial blood carbon dioxide tension ranged from normal to moderately elevated in the 14 patients. During the infusion of isoproterenol, carbon dioxide tension also fell slightly but significantly. For the most part, arterial blood oxyhemoglobin saturation was reduced in the control period. Although changes did occur following drug administration, the levels of the group as a whole were not significantly different from those of the control period. After isoproterenol administration, oxygen consumption rose.
Discussion
The well-known inotropic and chronotropic effects of isoproterenol are once again confirmed by this study. Of particular interest is the finding that the greatest increment in cardiac output was sustained by those patients having the highest initial right atrial pressures. Review of the studies of Schreiner and associates in patients with aortic valvular disease shows that the drug effected the greatest increase in blood flow in those who had the highest initial left atrial mean pressure (n= 11, r=0.681, P<0.02).6 If the level of the initial right (or left) atrial pressure is predominately a consequent of an increase in right (or left) ventricular volume and, hence, Circulation, Volume XLIII, April 1971 in diastolic fiber length, then shortening of these fibers might effect a greater increase in cardiac output than shortening of fibers of more normal length.17 The fall in wedge pressure with isoproterenol infusion, which was proportional to the initial level of pressure, is probably due to an analogous response to the drug.
The finding of a rise in pulmonary blood volume without a significant variation in the average level of pulmonary arterial or wedge pressures confirms the impressions of others that isoproterenol is a dilator of the pulmonary vasculature in patients with chronic obstructive lung disease.4' 5 Although the site of action of the drug is not identified, it is noteworthy that those patients with the lowest initial systemic arterial oxyhemoglobin saturations sustained the greatest increment in pulmonary blood volume. This suggests that either the drug effected the greatest response in those vessels constricted by hypoxia or that relaxation of vessels constricted by hypoxia resulted in a greater increase in their luminal diameter than did relaxation of blood vessels under less tension. Silove 25 one would have to postulate that the pulmonary arterial volume had doubled if the observed increment in total pulmonary blood volume were limited to this segment of the bed. It is more reasonable to infer that the venous portion of the bed also participated in this volume expansion, particularly since Brody and Stemmler have shown that the drug does cause pulmonary venous dilatation in dogs. 7 A simple vasodilating effect of isoproterenol on the pulmonary vascular bed may have been complicated by three other effects of the drug. Hyperventilation, in some instances, effected a rise in alveolar oxygen tension, as revealed by an increase in systemic arterial oxyhemoglobin saturation. Relief of hypoxia may well have contributed to pulmonary vasodilatation. Isoproterenol also produced changes in pulmonary wedge pressure, presumably as a consequence of its inotropic action. Variations in wedge pressure may be reflected in pulmonary arterial diastolic pressure in this type of patient8 and, therefore, may have masked or augmented any fall in pressure induced by the vasodilating action of the drug. Finally, the large increments in blood flow may have, to some extent, masked the vasodilating effects of the drug, at least as reflected by changes in pulmonary arterial diastolic pressure.
While it is possible to implicate an effect of the drug on muscular pulmonary arteries and pulmonary veins, it is not likely that isoproterenol affected the elastic pulmonary arteries. The systolic and mean pressures both before and after drug administration were predicted with equal accuracy from constants derived from normal data. If the compliance characteristics of the elastic arteries had been significantly altered by the drug, the effect of stroke volume on the pulse pressure also would have been altered, and the predicting equations would have failed to give the correct values after drug infusion and, thus, would no longer be applicable. Since the equations were equally applicable before and after drug administration, we can infer that there was no appreciable change in compliance and that isoproterenol affects the muscular pulmonary arteries rather than the elastic vessels.
